SEC Form 4/A · accession 0001856079-26-000002
Barinthus Biotherapeutics plc. · BRNS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 11:00 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001828185
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Sep 9, 2026 | U | 8,797,770 | $0.111 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share.
- F2Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the "Issuer") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement.
Remarks
In connection with the combination of Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc., Oxford Science Enterprises plc no longer beneficially owns more than 10% of the Issuer's Ordinary Shares, represented by American Depositary Shares. As a result, Oxford Science Enterprises plc is no longer subject to Section 16 of the U.S. Securities Exchange Act of 1934 with respect to the Issuer's Ordinary Shares and will no longer report transactions on Form 4 or Form 5.